Ep145: Lori Lyons-Williams on Targeted Radiopharmaceuticals for Cancer

Episode Summary

Executive Summary: Lori Lyons-Williams shares her path from rural Virginia and family-run restaurants to biotech CEO, highlighting how sales, marketing, and business training shaped her leadership. She explains why targeted radiopharmaceuticals are entering a new era, and how Abdera is using an engineered antibody platform to improve tumor delivery, reduce off-target exposure, and target hard-to-treat solid tumors like small cell lung cancer.

Main Topics: Early life and entrepreneurial roots (Priority: 5/5): Lyons-Williams describes growing up in rural Virginia in a family of restaurant and real-estate entrepreneurs, where customer interaction, hard work, and community shaped her instincts. From pre-med to pharmaceuticals (Priority: 5/5): She explains her pivot away from medicine after volunteer physicians warned her about the changing economics of healthcare, leading her into pharma sales and a long industry career. Career growth through sales, marketing, and business education (Priority: 5/5): At Johnson & Johnson and Allergan, she moved from sales rep to marketing and general management, while business school helped her learn finance, strategy, and company-building. Commercial lessons from Botox and large-company leadership (Priority: 4/5): Her Allergan experience showed how product repositioning, physician insight, and cross-functional collaboration can expand indications and build franchises. Shift to smaller biotech and company-building (Priority: 4/5): After leading through Allergan’s takeover and moving to Dermira and Numura, she sought earlier-stage roles to gain deeper responsibility for strategy, R&D, and capital allocation. Targeted radiopharmaceuticals and Abdera’s differentiation (Priority: 5/5): She argues the modality is at an inflection point due to strong clinical data, commercial traction from Pluvicto and Lutathera, and Abdera’s engineered antibody design that aims to improve PK, tumor uptake, and safety. Advice for women in biotech leadership (Priority: 4/5): She urges women to keep raising their hands, seek out mentors and strong teams, and not self-limit; she emphasizes mutual support among women leaders.

Key Arguments: Sales and marketing can be scientific and patient-centered when tied to real unmet need, physician insight, and data-driven positioning. Her early career success came from learning to listen to the field and repositioning products based on who actually used them, not who was initially assumed to use them. Large-company experience taught her how commercialization, R&D, and strategy must work together; good leaders should be willing to kill programs when science or commercial logic fails. Targeted radiopharmaceuticals are entering a new phase because newer products like Pluvicto and Lutathera have validated the platform commercially and clinically. Abdera’s approach is differentiated by engineered antibody pharmacokinetics designed to reduce kidney exposure and bone marrow toxicity while preserving tumor uptake. Small cell lung cancer is a compelling initial indication because it remains difficult to treat despite existing therapies and has high unmet need. For aspiring women leaders, self-advocacy, curiosity, and surrounding oneself with people who have complementary expertise are essential for advancement.

Data Points: Series A and B financing: $142 million - Abdera announced a combined financing round in April. Targeted radiopharmaceutical market size: $30 billion - Lyons-Williams cited this as the expected market opportunity before the end of the decade. Pluvicto annualized sales: about $1 billion - She used this as evidence that commercial success is now validating the modality. M&A activity in the space: about $10 billion - She attributed recent market momentum to acquisitions by Bayer and Novartis. Allergan tenure: 15 years - She spent 15 years at Allergan across sales, marketing, and general management roles. Upper Midwest sales territory: 15 or 16 states - As a region manager, she led a broad sales geography from Minneapolis. Dermira employee count: employee number 95 - She joined Dermira relatively late in its private-to-commercial evolution. Small cell lung cancer share of lung cancers: about 15% - She highlighted this subset as a difficult-to-treat indication. Small cell lung cancer five-year survival: less than 5% - She cited this as a marker of the severe unmet need. Untreated small cell lung cancer survival window: 6 to 8 weeks - She noted rapid deterioration without treatment. Radiation use in cancer treatment: more than 50% of all cancer cases - She emphasized radiation’s broad importance as a mainstay of oncology. Planned IND filing: 2024 - Abdera said it expects to file its first IND in 2024 for the DLL3 program.

Pivotal Quotes: "“I was never afraid to raise my hand and to say that I wanted to do something else, to learn something new.”" — Lori Lyons-Williams: Advice to women in biotech and a summary of her career philosophy. "“I think everything starts and begins and should always be driven by the science.”" — Lori Lyons-Williams: Her view of how R&D, commercialization, and strategy should interact. "“We’ve essentially dialed in the PK to what we believe is an ideal PK specifically suited for radiopharmaceuticals.”" — Lori Lyons-Williams: Explaining Abdera’s engineering strategy for targeting and safety.

Implications: The interview suggests radiopharmaceuticals may be moving from old, disappointing attempts to a credible cancer platform, with early data, better engineering, and new capital converging. For leaders, it underscores the value of cross-functional fluency and self-advocacy.